<DOC>
	<DOCNO>NCT01720550</DOCNO>
	<brief_summary>The objective study conduct trial spirit provide much possible benefit PG2 treatment eligible patient evaluate efficacy safety different dos PG2 treatment relieve fatigue among advanced cancer patient standard palliative care ( SPC ) hospice set curative option available . Patient 's fatigue status , measure Brief Fatigue Inventory-Taiwanese Form ( BFI-T ) , primary endpoint . The fatigue improvement response rate among patient two study arm compare basis efficacy evaluation end first treatment cycle , primary endpoint . Other endpoint , fatigue improvement response rate mean fatigue score change baseline among patient within cycle include secondary efficacy endpoint , compare two study arm . Patients ' quality sleep , appetite , pain , fatigue , nausea , vomit global quality life ( QoL ) also measure 11 question ( SS11 ) EORTC ( European Organization ) Research Treatment Cancer QLQ-C30 secondary endpoint evaluation . The secondary endpoint include Karnofsky performance score , weight change relate c-reactive protein level patient .</brief_summary>
	<brief_title>PG2 Treatment Improving Fatigue Among Advanced Cancer Patients Under Standard Palliative Care</brief_title>
	<detailed_description>This trial evaluate use different dos PG2 treatment fatigue improvement advance cancer patient standard palliative care hospice set curative option available . Only patient give consent participate study meet inclusion exclusion criterion eligible enroll study . All patient continue standard palliative care ( SPC ) study . The main aim trial compare improvement patient 's fatigue status patient different dos PG2 treatment . Patient 's fatigue status assess Brief Fatigue Inventory-Taiwanese ( BFI-T ) Form . Each patient 's fatigue improvement response define improvement mean fatigue score least 10 % baseline . Other quality life parameter measure 11 question ( SS11 ) EORTC QLQ-C30 Karnofsky performance scale . Patient 's weight change relate c-reactive protein follow . There two study arm trial : 1 ) PG2 High Dose arm ; 2 ) PG2 Low Dose arm .</detailed_description>
	<mesh_term>Fatigue</mesh_term>
	<criteria>Signed informed consent form ≧ 20 year old Have locally advance metastatic cancer inoperable advanced cancer Under standard palliative care ( SPC ) hospice set curative option available BFI score ≧ 4 Life expectancy least 3 month determine investigator Willing able complete quality life questionnaire Pregnant breastfeeding Uncontrolled systemic disease Take central nervous system stimulators within 30 day screen Have enrol yet complete investigational drug trial within 30 day screen Karnofsky Performance Scores less 30 % Diagnosed dying status</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2016</verification_date>
	<keyword>Cancer-related fatigue</keyword>
	<keyword>Palliative Treatment</keyword>
	<keyword>Astragalus polysaccharide</keyword>
</DOC>